In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback